Pulmonary Arterial Hypertension Market worth stood at $11.35 billion & 5.00% CAGR by 2032

Pulmonary Arterial Hypertension Market Size Worth $11.35 Billion By 2032 | CAGR: 5.00%

The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report “Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/pulmonary-arterial-hypertension-market/request-for-sample

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

  • In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.
  • During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.
  • In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.
  • The global key market players include Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Generics
  • Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Intravenous/ subcutaneous
  • Inhalational
  • Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Pulmonary Arterial Hypertension Market Report Scope

Report Attributes


Market size value in 2024

USD 7.68 billion

Revenue forecast in 2032

USD 11.35 billion


5.00% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

By Type, By Drug Class, Route of Administration, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report